Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167517 | 0.83 | ERCC5 (0.58) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL11830121 | 0.83 | L3MBTL1 (0.50) | MEN1KMT2AKDM4EALDH1A1MGAM | |
| SCHEMBL276803 | 0.82 | SMN1; SMN2 (0.61) | MEN1KMT2AKDM4EALDH1A1MGAM | |
| SCHEMBL1167344 | 0.81 | KDM4E (0.63) | MEN1KMT2AKDM4EALDH1A1MGAM | |
| SCHEMBL2459005 | 0.79 | MEN1 (0.59) | MEN1KMT2AKDM4EALDH1A1MGAM | |
| SCHEMBL11622169 | 0.79 | KDM4E (0.59) | MEN1KMT2AKDM4EALDH1A1MGAM | |
| SCHEMBL1348885 | 0.78 | KDM4E (0.51) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL31299787 | 0.78 | KDM4E (0.51) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL4263364 | 0.78 | SMN1; SMN2 (0.56) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL1437391 | 0.78 | MEN1 (0.48) | MEN1KMT2AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116023263-A | Synthesis method of intermediate 3- (3, 5-dichlorophenyl) -3-oxo-ethyl propionate | 苏州汉德创宏生化科技有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-116023263-A | Synthesis method of intermediate 3- (3, 5-dichlorophenyl) -3-oxo-ethyl propionate | 苏州汉德创宏生化科技有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-2440553-B1 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8470773-B2 | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470773-B2 | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120108505-A1 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION | 2012-05-03 | — | — | US | disclosed |
| US-20120108505-A1 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION | 2012-05-03 | — | — | US | disclosed |
| EP-2438070-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | disclosed |
| US-20110065634-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| WO-2010139483-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-7598285-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080167322-A1 | Substituted Pyrazoles as Modulators of Chemokine Receptors | MERCK SHARP & DOHME CORP. | 2008-07-10 | — | — | US | disclosed |
| EP-1853260-A1 | SUBSTITUTED PYRAZOLES AS MODULATORS OF CHEMOKINE RECEPTORS | Merck & Co., Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1756064-A2 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006088813-A1 | SUBSTITUTED PYRAZOLES AS MODULATORS OF CHEMOKINE RECEPTORS | MERCK & CO., INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2005121097-A2 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
| US-6544982-B1 | 3-aryl-5-aminoisoxazole derivatives | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108505-A1 | THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GPR119 | MEN1 2146/4885KMT2A 3628/4885KDM4E 3526/4885 |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PC, GOT2, PNLIP | MEN1 3060/4885KMT2A 4218/4885KDM4E 4338/4885 |
| US-20080167322-A1 | Substituted Pyrazoles as Modulators of Chemokine Receptors | CCR1, CCR3, CCR2 | MEN1 4495/4885KMT2A 4288/4885KDM4E 4538/4885 |
| US-20110065634-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | MEN1 738/4885KMT2A 3064/4885KDM4E 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.